Tactile Systems Technology, Inc. (TCMD) Bundle
Understanding Tactile Systems Technology, Inc. (TCMD) Revenue Streams
Understanding Tactile Systems Technology, Inc.’s Revenue Streams
The company reported a revenue increase of $3.5 million, or 5%, reaching $73.1 million for the three months ended September 30, 2024, compared to $69.6 million in the same period of 2023. The growth was driven by a $2.8 million increase, or 4%, in sales and rentals of the lymphedema product line, along with a $0.7 million increase, or 10%, in sales of the airway clearance product line.
For the nine months ended September 30, 2024, total revenue was $207.4 million, up $10.6 million, or 5%, from $196.8 million in the same period of 2023. This increase can be attributed to a $10.0 million rise, or 6%, in lymphedema product sales and rentals, and a $0.6 million increase, or 2%, in airway clearance product sales.
Revenue Breakdown by Product Line
The following table summarizes revenue by product line for the three and nine months ended September 30, 2024, and 2023:
| Period | Product Line | 2024 Revenue (in thousands) | 2023 Revenue (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|---|
| Three Months Ended September 30 | Lymphedema Products | $65,282 | $62,506 | $2,776 | 4% |
| Three Months Ended September 30 | Airway Clearance Products | $7,811 | $7,080 | $731 | 10% |
| Total | $73,093 | $69,586 | $3,507 | 5% | |
| Nine Months Ended September 30 | Lymphedema Products | $182,278 | $172,257 | $10,021 | 6% |
| Nine Months Ended September 30 | Airway Clearance Products | $25,121 | $24,514 | $607 | 2% |
| Total | $207,399 | $196,771 | $10,628 | 5% |
Contribution of Different Business Segments to Overall Revenue
For the three months ended September 30, 2024, the contribution to total revenue from each product line is as follows:
- Lymphedema Products: 89%
- Airway Clearance Products: 11%
For the nine months ended September 30, 2024, the revenue contribution remained consistent:
- Lymphedema Products: 88%
- Airway Clearance Products: 12%
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth reflects a consistent increase, with the following highlights:
- Three months ended September 30, 2024: 5% increase from 2023
- Nine months ended September 30, 2024: 5% increase from 2023
This growth rate indicates a stable demand for the company's products, particularly driven by enhancements in the sales team and strategic partnerships.
Significant Changes in Revenue Streams
The increase in revenue from the lymphedema product line is largely attributed to:
- Expansion of the field sales team
- Ongoing technology and workflow initiatives
In the airway clearance product line, revenue growth was primarily due to:
- Onboarding of a new durable medical equipment (DME) partner in 2024
These strategic moves have positively impacted revenue performance, showcasing the company's adaptability in the healthcare market.
A Deep Dive into Tactile Systems Technology, Inc. (TCMD) Profitability
A Deep Dive into Tactile Systems Technology, Inc. Profitability
Gross Profit Margin: For the three months ended September 30, 2024, the gross profit was $54.8 million, resulting in a gross profit margin of 75.0%. This is an increase from 70.9% in the same period of 2023. For the nine months ended September 30, 2024, gross profit was $152.3 million, with a gross margin of 73.4%, compared to 70.7% in 2023.
Operating Profit Margin: The income from operations for the three months ended September 30, 2024, was $9.7 million, yielding an operating profit margin of 13.3% compared to 8.9% in the same quarter of 2023. For the nine months, the operating profit was $26.9 million, reflecting an operating margin of 12.9%, up from 9.6% in 2023.
Net Profit Margin: The net income for the three months ended September 30, 2024, was $5.2 million, equating to a net profit margin of 7.1%, down from 31.9% for the same quarter in 2023. For the nine months, net income was $7.2 million, representing a net profit margin of 3.5%, compared to 10.3% in 2023.
| Metric | Q3 2024 | Q3 2023 | Change | 9M 2024 | 9M 2023 | Change |
|---|---|---|---|---|---|---|
| Gross Profit | $54.8 million | $49.4 million | +10.9% | $152.3 million | $139.1 million | +9.5% |
| Operating Income | $9.7 million | $6.2 million | +56.5% | $26.9 million | $18.9 million | +42.5% |
| Net Income | $5.2 million | $22.3 million | -76.7% | $7.2 million | $20.3 million | -64.7% |
Trends in Profitability: The profitability metrics indicate a mixed performance. While gross and operating profit margins have improved, net profit margin has significantly declined, highlighting challenges in overall profitability.
Comparison with Industry Averages: The average gross profit margin in the medical devices industry is around 65%, indicating that the company is performing above industry standards. Operating margins typically range from 10% to 15%, suggesting that the company is in line with industry expectations. However, the net profit margin being lower than the industry average of 10-15% suggests operational inefficiencies or increased expenses.
Operational Efficiency Analysis: The decrease in cost of revenue, which fell by 9% to $18.3 million in Q3 2024, has positively affected gross margins. However, the increase in total operating expenses by 7% to $142.7 million indicates potential areas for improvement in cost management, particularly in sales and marketing expenses, which rose by 3% to $82.8 million.
Debt vs. Equity: How Tactile Systems Technology, Inc. (TCMD) Finances Its Growth
Debt vs. Equity: How Tactile Systems Technology, Inc. Finances Its Growth
The company's financial structure is an essential aspect of its growth strategy. As of September 30, 2024, the total debt consists of:
- Long-term debt: $27.0 million
- Short-term debt: $2.9 million
The debt-to-equity ratio stands at 0.13, indicating a conservative approach to leveraging compared to the industry average of approximately 0.50.
Recent financing activities include:
- Repayment of the revolving credit facility amounting to $16.8 million on December 21, 2023.
- Outstanding borrowings under the Credit Agreement, which are all associated with the term loan, amount to $27.0 million as of September 30, 2024.
Interest on the term loan is calculated at an adjusted rate of 7.10%, with principal repayments required in quarterly installments of $750,000.
The following table summarizes the company's debt obligations and equity structure:
| Debt Type | Amount (in millions) | Interest Rate | Maturity |
|---|---|---|---|
| Long-term Debt | 27.0 | 7.10% | 2026 |
| Short-term Debt | 2.9 | N/A | 2024 |
| Total Liabilities | 79.8 | N/A | N/A |
| Total Stockholders' Equity | 207.9 | N/A | N/A |
In balancing debt financing with equity funding, the company has primarily relied on operational income and bank financing, alongside a public offering that generated $34.6 million in February 2023. As of September 30, 2024, total stockholders' equity was reported at $207.9 million, reflecting a strong capital base to support growth initiatives.
This approach allows the company to maintain flexibility while pursuing growth opportunities without excessively relying on debt, thereby minimizing financial risk.
Assessing Tactile Systems Technology, Inc. (TCMD) Liquidity
Assessing Tactile Systems Technology, Inc. Liquidity
As of September 30, 2024, Tactile Systems Technology, Inc. reported strong liquidity metrics characterized by cash and cash equivalents of $82.1 million and net accounts receivable of $43.2 million. In comparison, as of September 30, 2023, the company had cash and cash equivalents of $66.0 million and net accounts receivable of $58.5 million.
Current and Quick Ratios
The current ratio, which measures the company's ability to cover its short-term liabilities, can be calculated as follows:
| Metric | 2024 | 2023 |
|---|---|---|
| Current Assets | $125.3 million | $124.5 million |
| Current Liabilities | $65.0 million | $62.5 million |
| Current Ratio | 1.93 | 1.99 |
The quick ratio, which excludes inventory from current assets, is also an important measure:
| Metric | 2024 | 2023 |
|---|---|---|
| Quick Assets | $121.9 million | $120.3 million |
| Current Liabilities | $65.0 million | $62.5 million |
| Quick Ratio | 1.88 | 1.93 |
Analysis of Working Capital Trends
Working capital, defined as current assets minus current liabilities, was as follows:
| Year | Working Capital |
|---|---|
| 2024 | $60.3 million |
| 2023 | $62.0 million |
This indicates a slight decrease in working capital year-over-year, reflecting changes in both current assets and liabilities.
Cash Flow Statements Overview
The cash flow from operating, investing, and financing activities for the nine months ended September 30, 2024, is summarized below:
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Provided by Operating Activities | $24,322 | $17,503 |
| Net Cash Used in Investing Activities | ($2,005) | ($1,541) |
| Net Cash Used in Financing Activities | ($1,204) | $28,145 |
| Net Increase in Cash and Cash Equivalents | $21,113 | $44,107 |
Potential Liquidity Concerns or Strengths
While the company has demonstrated strong liquidity with significant cash reserves, the reduction in working capital and net increase in cash flow from operations indicates potential areas for improvement in managing current liabilities. The cash flow from operations has increased significantly from $17.5 million in 2023 to $24.3 million in 2024, indicating a positive trend in operational efficiency.
Overall, Tactile Systems Technology, Inc. maintains a solid liquidity position with a current ratio above 1.9, suggesting adequate coverage of short-term obligations while also highlighting areas for strategic management of working capital.
Is Tactile Systems Technology, Inc. (TCMD) Overvalued or Undervalued?
Valuation Analysis
To determine whether the company is overvalued or undervalued, we will analyze key financial ratios including price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA), examine stock price trends over the last 12 months, evaluate dividend yield and payout ratios, and review analyst consensus on stock valuation.
Price-to-Earnings (P/E) Ratio
The P/E ratio is calculated as the stock price divided by earnings per share (EPS). As of September 30, 2024, the diluted EPS was $0.21. Assuming the stock price is $24, the P/E ratio is:
P/E Ratio = Stock Price / EPS = $24 / $0.21 = 114.29
Price-to-Book (P/B) Ratio
The P/B ratio is calculated as the stock price divided by book value per share. The total equity as of September 30, 2024, was $207.9 million, with 23,997,089 shares outstanding. The book value per share is:
Book Value per Share = Total Equity / Shares Outstanding = $207,901,000 / 23,997,089 = $8.66
P/B Ratio = Stock Price / Book Value per Share = $24 / $8.66 = 2.77
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
To calculate the EV/EBITDA ratio, we need the enterprise value and EBITDA. As of September 30, 2024, the total debt was $30 million, and cash and cash equivalents were $82.1 million. The enterprise value (EV) is calculated as follows:
EV = Market Capitalization + Total Debt - Cash = ($24 23,997,089) + $30,000,000 - $82,100,000 = $567,000,000
EBITDA for the nine months ended September 30, 2024, was $9.7 million.
EV/EBITDA Ratio = EV / EBITDA = $567,000,000 / $9,700,000 = 58.5
Stock Price Trends
Over the past 12 months, the stock price has experienced fluctuations. The stock price was approximately $20 a year ago and has increased to $24, representing a 20% increase.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, resulting in a dividend yield of 0% and a payout ratio of 0%.
Analyst Consensus on Stock Valuation
As of October 2024, the consensus among analysts is mixed, with recommendations to hold the stock based on current valuations and market conditions.
| Valuation Metrics | Value |
|---|---|
| P/E Ratio | 114.29 |
| P/B Ratio | 2.77 |
| EV/EBITDA Ratio | 58.5 |
| Stock Price (Current) | $24 |
| Stock Price (1 Year Ago) | $20 |
| Dividend Yield | 0% |
| Payout Ratio | 0% |
| Analyst Consensus | Hold |
Key Risks Facing Tactile Systems Technology, Inc. (TCMD)
Key Risks Facing Tactile Systems Technology, Inc.
The company faces a variety of internal and external risks that can significantly impact its financial health. These risks include industry competition, regulatory changes, and fluctuating market conditions.
Industry Competition
Competition in the medical device industry is intense, with numerous established players and new entrants. The company’s primary product lines, including lymphedema and airway clearance products, are subject to price competition and innovation pressures. As of September 30, 2024, revenue from lymphedema products was $182.3 million, accounting for 88% of total revenue, while airway clearance products generated $25.1 million, representing 12%.
Regulatory Changes
The company operates within a heavily regulated environment. Changes in healthcare regulations can affect reimbursement rates, product approval processes, and operational costs. The company has invested in its reimbursement function to improve operational efficiencies, which is crucial for navigating these regulatory landscapes.
Market Conditions
Current economic conditions, including inflation and interest rate fluctuations, pose risks to demand for the company’s products. A general economic downturn could reduce consumer spending on healthcare products. For the nine months ended September 30, 2024, net income was $7.2 million, a decline of 64% compared to $20.3 million in the same period of 2023.
Operational Risks
Operational risks include reliance on third-party manufacturers for component sourcing and assembly. Any disruptions in these relationships could affect production capabilities. As of September 30, 2024, cash and cash equivalents stood at $82.1 million, reflecting the company's liquidity position amidst operational challenges.
Financial Risks
Financial risks are highlighted in the company’s earnings reports, particularly related to income tax expenses. For the three months ended September 30, 2024, the company recorded an income tax expense of $2.1 million, contrasting with an income tax benefit of $14.7 million in the same period of 2023.
Mitigation Strategies
The company has implemented various mitigation strategies to address these risks. This includes enhancing its reimbursement operations, improving payer relations, and focusing on product innovation to maintain competitive advantages. The company’s investment in research and development (R&D) expenses increased 23% to $2.4 million for the three months ended September 30, 2024.
| Risk Factor | Description | Recent Financial Impact |
|---|---|---|
| Industry Competition | Pressure from established and new entrants | Revenue from lymphedema products: $182.3 million |
| Regulatory Changes | Impact on approvals and reimbursement | Investment in reimbursement function |
| Market Conditions | Economic downturns affecting demand | Net income decline: 64% year-over-year |
| Operational Risks | Dependence on third-party manufacturers | Cash and cash equivalents: $82.1 million |
| Financial Risks | Income tax fluctuations | Income tax expense: $2.1 million |
Future Growth Prospects for Tactile Systems Technology, Inc. (TCMD)
Future Growth Prospects for Tactile Systems Technology, Inc.
Analysis of Key Growth Drivers
Product innovations play a significant role in driving future growth. The company recently launched the Kylee™ mobile app, which enhances patient management by tracking treatments and symptoms. This innovation aligns with ongoing technology initiatives aimed at improving patient engagement and outcomes.
Market expansions are also on the horizon, particularly through the onboarding of new durable medical equipment (DME) partners. This initiative is expected to increase the reach of the airway clearance product line, which has already shown a revenue increase of 10% in the three months ended September 30, 2024.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, total revenue reached $207.4 million, a 5% increase compared to $196.8 million for the same period in 2023. The growth was driven by a 6% increase in lymphedema product sales, contributing $182.3 million in revenue. The company projects continued revenue growth as it expands its product offerings and market presence.
Strategic Initiatives or Partnerships That May Drive Future Growth
The company has entered into strategic partnerships to enhance its payer relations function, which focuses on policy development and contract negotiations. These relationships are crucial for expanding product accessibility and adoption across various insurance providers.
Competitive Advantages That Position the Company for Growth
The company benefits from a strong brand presence and a diverse product portfolio that includes both sales and rental revenue streams. For the three months ended September 30, 2024, sales revenue accounted for 86% of total revenue, while rental revenue contributed 14%. This dual revenue model provides financial stability and growth opportunities.
| Period | Total Revenue (in thousands) | Growth Rate | Lymphedema Products Revenue (in thousands) | Airway Clearance Products Revenue (in thousands) |
|---|---|---|---|---|
| Q3 2024 | $73,093 | 5% | $65,282 | $7,811 |
| Q3 2023 | $69,586 | - | $62,506 | $7,080 |
| 9M 2024 | $207,399 | 5% | $182,278 | $25,121 |
| 9M 2023 | $196,771 | - | $172,257 | $24,514 |
The company’s gross margin improved to 75.0% in Q3 2024, compared to 70.9% in Q3 2023. This improvement is indicative of enhanced operational efficiency and cost management, which are critical for sustaining growth in a competitive landscape.
Overall, the combination of product innovation, market expansion, strategic partnerships, and strong financial performance positions the company favorably for future growth.
Tactile Systems Technology, Inc. (TCMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Tactile Systems Technology, Inc. (TCMD) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Tactile Systems Technology, Inc. (TCMD)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Tactile Systems Technology, Inc. (TCMD)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.